Tripos and Crown Partners Form Strategic Alliance to Strengthen Drug Discovery Knowledge Management Solutions
Tripos, Inc., and Crown Partners LLC today announced the formation of a strategic relationship combining Crown Partners’ enterprise-scale content management solution with Tripos’ electronic notebook offering. The relationship strengthens the Tripos Electronic Notebook(TM) solution by including best-of-breed workflow, collaboration and content management technologies from Documentum, and provides the electronic notebook with comprehensive support for intellectual property issues involved in the research and development life cycle.
Through a combination of leading expertise in chemistry research, best practice consulting, and the development of innovative drug discovery informatics technologies, Tripos implements custom notebook solutions that best fit the scientific workflow and business goals of its customers. The core technologies used within the Tripos Electronic Notebook were developed in collaboration with a leading pharmaceutical company to document and share scientific information, and eliminate storage of laboratory data in disparate archives.
“Laboratory informatics technologies must seamlessly align with an organization’s overall knowledge management strategy, especially enterprisewide systems like electronic notebooks,” said Dr. Trevor Heritage, senior vice president and general manager of Discovery Informatics at Tripos. “Crown Partners’ exclusive status as a Documentum Signature Partner provides Tripos’ clients with a unique combination of strength in e-notebooks and content management technologies.”
Crown Partners has expertise developing standardized processes and content management solutions that leverage the Documentum Enterprise Content Management platform with extensive experience in scalable processes and technologies.
“Crown Partners selects only best-of-breed technology partners to deliver its enterprise content management solutions,” said Richard Hearn, senior managing partner of Crown Partners Consulting Group. “Tripos’ chemistry and informatics experience provides a truly unique perspective for the drug discovery sector and is a good addition to our partner strategy.”
About Crown Partners Consulting Group
Crown Partners is a leading niche consulting and systems integration firm focused on delivering enterprise-scale content management solutions to the Fortune 1000. We believe our resources are the best in the industry at making your solution a success. The Crown Partners domain includes leading Content Management packages, such as Documentum, Document Sciences, Captiva Software, and others. For more information about Crown Partners Services, please call us at 937-439-7970, or visit the Crown Partners website at www.crownpartners.com .
About Tripos
Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com .
This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as “expects,” “anticipates,” “projects,” “estimates,” “intends,” “plans,” “believes,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.
